Joint (NASDAQ:JYNT) Issues Earnings Results

Joint (NASDAQ:JYNT) issued its quarterly earnings data on Thursday. The company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05, FiscalAI reports. Joint had a net margin of 6.49% and a return on equity of 11.70%. The business had revenue of $15.18 million during the quarter, compared to analyst estimates of $14.57 million.

Here are the key takeaways from Joint’s conference call:

• Profitability and cash flow improved sharply: Q2 revenue rose 14% to $15.2 million, Adjusted EBITDA from continuing operations increased to $1.5 million from $88,000, and free cash flow grew $1.6 million to $1.9 million.
• Refranchising is nearing completion, with clinic ownership transfers and management service agreements progressing across the three sale bundles. Once finalized, The Joint expects to have only three remaining company-owned or managed clinics, supporting a more capital-light model.
• Patient retention reached its best level in more than five years following the rollout of flexible membership options, while active-member trends improved sequentially. Management also reported no meaningful patient pushback to price increases implemented at more than 500 clinics.
• System-wide sales declined 3.7% year over year and Q2 comparable sales were negative 2.8%, although management said July and second-half trends were improving.
• The company reduced its 2026 new-clinic opening outlook to 22–26 from 30–35, and expects year-end clinic count to be below 2025 levels as closures and portfolio optimization offset new openings. Full-year guidance was otherwise reiterated, including $12.5 million–$13.5 million of consolidated Adjusted EBITDA.

Joint Trading Up 1.3%

JYNT traded up $0.11 during midday trading on Friday, reaching $8.33. The company’s stock had a trading volume of 104,765 shares, compared to its average volume of 60,308. The firm has a market capitalization of $118.79 million, a price-to-earnings ratio of 30.85 and a beta of 1.10. Joint has a 1 year low of $7.50 and a 1 year high of $11.26. The stock’s 50-day moving average is $8.76 and its 200-day moving average is $8.87.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on JYNT. Zacks Research lowered shares of Joint from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Weiss Ratings raised shares of Joint from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, June 12th. Finally, Wall Street Zen upgraded shares of Joint from a “buy” rating to a “strong-buy” rating in a report on Saturday. Three research analysts have rated the stock with a Hold rating, According to MarketBeat, Joint presently has a consensus rating of “Hold”.

Insider Buying and Selling at Joint

In other Joint news, major shareholder Charles E. Jobson bought 127,676 shares of the stock in a transaction dated Tuesday, May 12th. The stock was purchased at an average cost of $8.57 per share, for a total transaction of $1,094,183.32. Following the completion of the acquisition, the insider owned 1,773,479 shares of the company’s stock, valued at approximately $15,198,715.03. This trade represents a 7.76% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 30.20% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its stake in Joint by 104.7% during the third quarter. BNP Paribas Financial Markets now owns 2,935 shares of the company’s stock valued at $28,000 after buying an additional 1,501 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Joint by 32.3% in the second quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock worth $86,000 after acquiring an additional 1,810 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Joint by 25.9% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock worth $95,000 after acquiring an additional 1,698 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Joint during the fourth quarter valued at $124,000. Finally, Wells Fargo & Company MN increased its holdings in shares of Joint by 78.0% during the fourth quarter. Wells Fargo & Company MN now owns 15,476 shares of the company’s stock valued at $135,000 after acquiring an additional 6,784 shares in the last quarter. Institutional investors own 76.88% of the company’s stock.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.